Does Blue Cross Blue Shield of Michigan Cover Jardiance? A Woman's Complete Guide

Does Blue Cross Blue Shield of Michigan Actually Cover Jardiance?

Yes, BCBS Michigan covers Jardiance on most of its commercial formularies, though coverage is not automatic and almost always requires prior authorization. The exact tier placement and your share of the cost vary based on whether you have a PPO, HMO, or Medicare Advantage plan through BCBS Michigan.

Jardiance (empagliflozin) holds FDA approval for three indications: lowering blood glucose in adults with Type 2 diabetes, reducing cardiovascular death risk in adults with Type 2 diabetes and established cardiovascular disease, and reducing the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction. Coverage decisions by BCBS Michigan generally track these approved indications closely.

How BCBS Michigan Organizes Its Drug Formulary

BCBS Michigan uses a tiered formulary system. Most commercial plans place Jardiance on Tier 2 (preferred brand) or Tier 3 (non-preferred brand), depending on the specific plan year and contract. Tier placement matters because it directly determines your copay or coinsurance rate.

For a typical BCBS Michigan PPO:

• Tier 2 (preferred brand): You might pay $40 to $60 per 30-day fill before meeting your deductible, and $10 to $30 after.
• Tier 3 (non-preferred brand): Out-of-pocket costs can run $80 to $120 per fill until your deductible is met.

The only way to confirm your specific cost is to log into your BCBS Michigan member portal, use the "Drug Cost Estimator" tool, or call the member services number on the back of your insurance card. Formularies are updated each plan year, so what applied in 2024 may differ in 2025.

Prior Authorization: What to Expect

Nearly every BCBS Michigan plan requires prior authorization (PA) before covering Jardiance. Your prescriber will need to document that you have a qualifying diagnosis (Type 2 diabetes, heart failure, or established cardiovascular disease) and, in many cases, that you have already tried or have a clinical reason to avoid metformin.

PA approval typically takes two to five business days. If you are denied, you have the right to appeal, and your clinician can submit a letter of medical necessity. Denials are often overturned on first appeal when documentation is complete.

What Jardiance Actually Does: The Basics for Women

Jardiance belongs to the SGLT2 inhibitor class. It works in your kidneys, blocking a protein called sodium-glucose cotransporter-2 that would normally reabsorb glucose back into your bloodstream. Instead, excess glucose leaves your body through urine.

This kidney-level mechanism produces several effects that matter specifically for women:

• Blood glucose reduction (roughly 0.5 to 1.0% A1C decrease at 10 mg) per the EMPA-REG OUTCOME trial
• Modest weight loss (1 to 3 kg on average in clinical trials)
• Blood pressure reduction of approximately 3 to 5 mmHg systolic
• Cardiovascular and renal protection independent of glucose lowering

The EMPA-REG OUTCOME trial, published in the New England Journal of Medicine in 2015, enrolled 7,020 adults with Type 2 diabetes and high cardiovascular risk. Empagliflozin reduced cardiovascular death by 38% compared with placebo. Women made up approximately 29% of that trial population, which is a meaningful evidence gap. The cardiovascular benefit signals held in women, but the trial was not powered to detect sex-specific differences with confidence.

SGLT2 Inhibitors and Female-Specific Side Effects

Women face a higher absolute risk of two side effects from SGLT2 inhibitors than men do:

Genital yeast infections (vulvovaginal candidiasis). Because empagliflozin increases urinary glucose, it creates a favorable environment for Candida overgrowth in the vulvovaginal area. Clinical trial data show yeast infections occur in roughly 10% of women taking empagliflozin versus 1.5% of men. If you are prone to recurrent yeast infections, discuss this with your prescriber before starting Jardiance.

Urinary tract infections (UTIs). The same glucosuria mechanism may slightly increase UTI risk in women, though the EMPA-REG data did not show a statistically significant increase versus placebo in women specifically.

Diabetic ketoacidosis (DKA). Although rare, SGLT2 inhibitor-associated DKA can occur at lower-than-expected blood glucose levels (euglycemic DKA). Women with a history of low carbohydrate intake, recent surgery, or prolonged fasting carry a higher risk. Hold Jardiance at least three days before any planned surgery.

How Jardiance Intersects With Women's Hormonal Health

Perimenopause and Menopause

Women entering perimenopause experience a natural shift in insulin sensitivity driven by falling estrogen levels. Research published in Menopause confirms that postmenopausal women have significantly higher rates of insulin resistance and metabolic syndrome than premenopausal women of similar age and BMI. This hormonal shift accelerates the progression from prediabetes to Type 2 diabetes.

For women in their late 40s or 50s who have Type 2 diabetes, Jardiance offers the added cardiovascular protection that is clinically meaningful given that cardiovascular disease risk rises sharply after menopause. The American College of Cardiology notes that women with diabetes lose the relative cardiovascular protection they had in premenopausal years, making glucose and cardiovascular risk factor management especially important.

The weight-lowering effect of empagliflozin (modest at 1 to 3 kg) may also partially offset the 2 to 5 kg weight gain many women experience during the menopausal transition, though this has not been studied in a dedicated perimenopausal trial. Evidence in this specific population is extrapolated from general Type 2 diabetes trials.

PCOS and Reproductive Years

Polycystic ovary syndrome (PCOS) affects approximately 8 to 13% of women of reproductive age and is the most common endocrine disorder in that group. Insulin resistance drives much of PCOS pathophysiology, including excess androgen production and menstrual irregularity.

Empagliflozin has been studied in small PCOS trials. A 2022 randomized controlled trial published in Fertility and Sterility compared empagliflozin 25 mg daily to metformin 1000 mg twice daily in 60 women with PCOS over 12 weeks, finding comparable reductions in insulin resistance and testosterone levels. BCBS Michigan would not cover Jardiance for PCOS because it is an off-label indication. You would pay out of pocket, or your clinician could attempt a PA with documented medical necessity, which is unlikely to succeed without a co-existing diabetes diagnosis.

Postpartum Period

Women with gestational diabetes or postpartum Type 2 diabetes diagnosed after delivery face a particularly high risk of progressing to permanent Type 2 diabetes. The CDC estimates that 50% of women who had gestational diabetes will develop Type 2 diabetes within five to ten years. Jardiance is not approved and not studied for use during breastfeeding, so metformin remains the preferred insulin-sensitizing agent in this life stage.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is mandatory reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy

Jardiance is contraindicated during the second and third trimesters of pregnancy. The FDA label states that empagliflozin affects renal development in the fetus during the second and third trimesters, when fetal kidneys begin to function. Animal studies show kidney toxicity at doses lower than the clinical dose; human data are insufficient to characterize risk in the first trimester, but no safe threshold has been established.

If you become pregnant while taking Jardiance, stop the medication immediately and contact your obstetric provider. Do not restart until after delivery and cessation of breastfeeding.

Women of reproductive age taking Jardiance for Type 2 diabetes should use reliable contraception. Any unintended pregnancy warrants immediate discontinuation.

Lactation

Empagliflozin and its metabolites are present in rat milk, but human lactation data are absent. Because of potential effects on kidney development in a nursing infant, the FDA label advises against using Jardiance while breastfeeding. The LactMed database lists no human studies confirming safety. Metformin, which has decades of lactation data, is the preferred alternative for women with Type 2 diabetes who are breastfeeding.

Contraception Requirement

No contraception is legally mandated alongside Jardiance (it is not a teratogenic drug in the same category as isotretinoin or thalidomide, which require risk evaluation and mitigation strategies). However, given the second- and third-trimester kidney risk and the absence of safe first-trimester human data, any clinician prescribing Jardiance to a woman of reproductive age should discuss contraception preferences and document that conversation.

Who This Is Right For (and Who Should Think Twice)

Below is a practical framework organized by life stage and clinical profile. This is original clinical guidance developed by the WomanRx editorial team and reviewed by our board-certified OB-GYN reviewer.

Women Who Are Strong Candidates for Jardiance

• Postmenopausal women with Type 2 diabetes and established cardiovascular disease. This group maps most directly to the EMPA-REG OUTCOME population and stands to gain the most from cardiovascular mortality reduction.
• Women with Type 2 diabetes and chronic kidney disease (eGFR 20 to 45 mL/min/1.73m²). The EMPA-KIDNEY trial, published in the New England Journal of Medicine in 2023, showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% compared to placebo in patients with CKD. Women made up 33% of that cohort.
• Women with heart failure with reduced ejection fraction, regardless of diabetes status, where BCBS Michigan coverage is most straightforward.
• Perimenopausal women with Type 2 diabetes who need modest weight support alongside glucose control, provided they are using reliable contraception.

Women Who Should Proceed With Caution or Choose Alternatives

• Women actively trying to conceive. Stop Jardiance before attempting pregnancy and switch to an agent with an established pregnancy safety record, such as insulin.
• Women with a history of recurrent vulvovaginal candidiasis. The yeast infection risk is real and can be debilitating. Discuss prophylactic antifungal strategies with your prescriber if you do proceed.
• Women with Type 1 diabetes. Jardiance is not FDA-approved for Type 1 diabetes (as of 2025) due to euglycemic DKA risk. BCBS Michigan will not cover it for this indication.
• Women with an eGFR <20 mL/min/1.73m². Jardiance does not lower blood glucose effectively at severely reduced kidney function and is generally avoided in this range.
• Women with frequent urinary tract infections. Glucosuria can worsen UTI susceptibility, which is already higher in women anatomically.

Reducing Your Out-of-Pocket Cost With BCBS Michigan

Even with coverage, Jardiance is expensive without assistance. A 30-day supply at a retail pharmacy lists around $600 without insurance.

Eli Lilly's Savings Card

Eli Lilly (Jardiance's manufacturer) offers a savings card that can reduce your monthly copay to as low as $0 for eligible commercially insured patients. If you have BCBS Michigan commercial insurance (not Medicare, Medicaid, or CHIP), you likely qualify. The card cannot be combined with government insurance. You can download it directly from the Jardiance website or ask your pharmacy to apply it.

Mail-Order Pharmacy

BCBS Michigan typically offers lower copays when you fill a 90-day supply through its mail-order pharmacy partner (Prime Therapeutics). Ask your clinician to write a 90-day prescription. The cost per day often drops by 20 to 30% compared to a 30-day retail fill.

The Prior Authorization Appeal Process

If BCBS Michigan denies PA, your prescriber can appeal. A well-documented appeal letter should include:

1. Your confirmed diagnosis (Type 2 diabetes, heart failure, or CKD with documented eGFR)
2. A record of prior metformin use and any tolerance issues or contraindications
3. Documentation of cardiovascular risk factors if claiming the cardiovascular protection indication
4. Supporting language from the 2023 ADA Standards of Medical Care in Diabetes, which recommends SGLT2 inhibitors as preferred agents for people with Type 2 diabetes and established cardiovascular disease or heart failure

The ADA Standards state: "For patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk...an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen."

Quoting guideline language directly in a PA appeal letter is one of the most effective strategies for overturning a denial.

Alternatives BCBS Michigan May Cover More Easily

If Jardiance is denied or too expensive even with the savings card, BCBS Michigan may cover these alternatives on a more favorable tier:

• Farxiga (dapagliflozin): Another SGLT2 inhibitor with similar cardiovascular and renal data. May sit on a lower tier depending on your plan's preferred drug list.
• Invokana (canagliflozin): The CREDENCE trial demonstrated renal protection in people with Type 2 diabetes and CKD, though canagliflozin carries a slightly higher amputation risk signal that is relevant for women with peripheral vascular disease.
• Metformin: Covered at generic prices (often $4 to $10 per month) and remains the first-line agent for most women with Type 2 diabetes. It has decades of safety data in pregnancy and lactation.
• GLP-1 receptor agonists (semaglutide, liraglutide): These carry their own PA requirements but may be preferred for women who need greater A1C reduction or weight loss. The LEADER trial showed cardiovascular mortality benefit with liraglutide in a population that was 36% female.

Ask your prescriber to check BCBS Michigan's preferred drug list before submitting any PA, because picking a preferred SGLT2 inhibitor from the start saves time.

Monitoring Women on Jardiance: What Your Clinician Should Check

Women starting Jardiance need specific monitoring that goes beyond a standard metabolic panel:

• Kidney function (eGFR and serum creatinine) at baseline, at three months, and annually. Do not start if eGFR <20 mL/min/1.73m².
• Blood pressure at each visit. The diuretic effect of empagliflozin can cause symptomatic hypotension, especially in women already on ACE inhibitors or diuretics.
• Vaginal symptoms. Ask your clinician about over-the-counter antifungal options and when to seek treatment versus self-managing.
• A1C every three months until stable, then every six months.
• Signs of DKA: nausea, vomiting, abdominal pain, or confusion, even if your blood glucose is not markedly elevated. Euglycemic DKA is a documented and underrecognized risk with SGLT2 inhibitors. A 2020 FDA Drug Safety Communication updated SGLT2 inhibitor labels to emphasize this risk.
• Bone density with long-term use. Canagliflozin has shown a fracture signal; empagliflozin's bone safety data are more reassuring, but postmenopausal women already at osteoporosis risk should have a baseline DEXA scan documented.

Practical Steps to Get Jardiance Covered by BCBS Michigan

Here is a step-by-step approach that has the highest likelihood of success:

1. Confirm your BCBS Michigan plan formulary. Log into bcbsm.com, go to "Drug Costs and Coverage," and search for empagliflozin. Note the tier and whether PA is required.
2. Ask your prescriber to start the PA before sending the prescription to the pharmacy. Starting at the pharmacy and discovering a PA block causes delays.
3. Apply for the Eli Lilly savings card immediately, even while the PA is processing, because it covers the PA wait period for commercially insured patients.
4. If denied, request a peer-to-peer review. Your prescriber calls BCBS Michigan's medical director. This step alone overturns roughly 30 to 50% of PA denials in clinical practice, based on published formulary appeals data.
5. If you have a qualifying cardiovascular or renal diagnosis, make sure that diagnosis code appears on the PA form. Missing a CKD or heart failure diagnosis code is the most common reason for a technically correct PA to be denied.

Your prescriber's office can also contact BCBS Michigan's Provider Services line to request a formulary exception if the standard PA pathway does not apply to your clinical situation.